PhIB Trial Lacutamab in Patients with Relapse Peripheral T-Cell Lymphoma that Express KIR3DL2

Official Title

A Multi-Center Phase IB Trial Evaluating the Safety and Efficacy of Lacutamab in Patients with Relapse Peripheral T-Cell Lymphoma that Express KIR3DL2

Details

This is a multi-center phase Ib sutdy, which evaluates the safety and efficacy of lacutamab monotherpy in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.

You can join if...

AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements

You can participate in this study if you

• must be 18 years of age or older

Exclusion Requirements.

You cannot participate in this study if you

• are pregnant or breast-feeding